Cargando…

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a narrow therapeutic range and demonstrates wide interindividual variability in pharmacokinetics, leading to potential underimmunosuppression or toxicity. Genetic polymorphism in CYP3A5 enzyme expression contributes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lucy, Prasad, G V Ramesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846312/ https://www.ncbi.nlm.nih.gov/pubmed/29563827 http://dx.doi.org/10.2147/PGPM.S107710

Ejemplares similares

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience
por: Patel, Mohan, et al.
Publicado: (2014)

Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India
por: Prasad, Narayan, et al.
Publicado: (2019)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients
por: Li, Chuan-Jiang, et al.
Publicado: (2014)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
por: Katsakiori, Paraskevi F, et al.
Publicado: (2010)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients
por: Htun, Yi Yi, et al.
Publicado: (2020)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study
por: Lenain, Rémi, et al.
Publicado: (2021)

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis
por: Shi, Wei-Long, et al.
Publicado: (2015)

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
por: Pasternak, Amy L, et al.
Publicado: (2021)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation
por: Niioka, Takenori, et al.
Publicado: (2015)

Beyond Single Nucleotide Polymorphisms: CYP3A5(∗)3(∗)6(∗)7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients
por: Brazeau, Daniel A., et al.
Publicado: (2020)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients
por: Katsakiori, Paraskevi F., et al.
Publicado: (2011)

Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2022)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Massive pleural effusion in a renal transplant recipient on tacrolimus
por: Nayagam, L. S., et al.
Publicado: (2014)

Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
por: Warzyszyńska, Karola, et al.
Publicado: (2022)

Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation
por: Nakamura, Takahiro, et al.
Publicado: (2020)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
por: Okabayashi, Shinji, et al.
Publicado: (2019)

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients
por: Alghamdi, Alaa, et al.
Publicado: (2023)

Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
por: Raj, T. Yashwanth, et al.
Publicado: (2022)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy
por: Khanna, Ashwani, et al.
Publicado: (2002)

Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients
por: Yan, Lin, et al.
Publicado: (2019)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: Thölking, Gerold, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ailpaa887gf64pm80mmtvairra